Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 9,443 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Activity Clear all
Withdrawn No phase listed Observational

Concussion Goody Bag Study

NCT07884604
View directory record Official record
Conditions
Sports Related Concussion
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using a Mentoring Afterschool Program to Improve Adolescent Mental Health and Physical Activity: A Pilot Study

NCT06686784
View directory record Official record
Conditions
Depression
Interventions
After School Plus
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
9 Years to 99 Years
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

NCT00615433
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

NCT01431690
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
warfarin, omefas, omega-3-acid ethyl esters
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Exercise of Secreted Factors From Muscle and Adipose Tissue

NCT02565823
View directory record Official record
Conditions
Healthy
Interventions
Exercise bout
Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 26, 2026, 2:46 AM EDT
Withdrawn Not applicable Interventional

Impact of Exercise on Body Composition in Premature Infants

NCT01386190
View directory record Official record
Conditions
Body Composition, Beneficial
Interventions
Exercise/Social Behavioral
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
29 Weeks to 34 Weeks
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 26, 2026, 2:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

(MIST2)-Part2: AEs Following DC Care at DC Teaching Clinic: Electronic

NCT03412110
View directory record Official record
Conditions
Patient Safety, Manipulation, Spinal
Interventions
active surveillance: electronic platform
Other
Lead sponsor
Parker University
Other
Eligibility
Not listed
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Not applicable Interventional

Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease

NCT02022423
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Telephone counseling, Internet-based walking program
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 26, 2026, 2:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

NCT06121297
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis
Interventions
CABA-201
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
12 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Orange, California • Sacramento, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Not applicable Interventional

Social Media Intervention - Physical Activity

NCT04901910
View directory record Official record
Conditions
Cannabis Use
Interventions
Physical Activity (PA) Social Media Group, Verdi plus PA Social Media Group
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

NCT02993159
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 26, 2026, 2:46 AM EDT
Terminated Phase 2 Interventional

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01579279
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-652 6 mg, ABT-652 12 mg, ABT-652 12 mg - 18 mg, Placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Anaheim, California • Walnut Creek, California • Milford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

NCT03689010
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid foam 15%, Finacea® (Azelaic acid Foam) 15%, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 26, 2026, 2:46 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Everyday Activity Shoes: a Quantification of Impact Forces While Walking

NCT04197362
View directory record Official record
Conditions
Impact Forces
Interventions
Evaluation
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

NCT02451696
View directory record Official record
Conditions
Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Interventions
Everolimus
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mothers and Girls Dancing Together Trial

NCT01588379
View directory record Official record
Conditions
Physical Activity
Interventions
Girls and mothers Afro-centric dance program, Girls, alone, Newsletter
Behavioral · Other
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
7 Years to 11 Years · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Contextually Cued PA Habits

NCT04691596
View directory record Official record
Conditions
Exercise
Interventions
Non-cue-contingent weekly incentives, Cue-contingent weekly incentives, Habit Coaching, App use instructions
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Troy, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

NCT03691662
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
34
States / cities
Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.

NCT00891046
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Louisville, Kentucky • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

NCT05140096
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Fluconazole, Isavuconazole
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)

NCT00483496
View directory record Official record
Conditions
Idiopathic Solar Urticaria
Interventions
Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209), Ti02 pigmentary 3% alone (formula RV3131A-MV1211), bisoctrizole 10% alone (formula RV3131A-MV1237), Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213), Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329), Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212), Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)], V0096 CR vehicle (formula RV3131A-MV1197)
Drug
Lead sponsor
Orfagen
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

NCT01242488
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc, Placebo iv
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
74
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 26, 2026, 2:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An fMRI Study of Opioid-related Changes in Neural Activity

NCT02818036
View directory record Official record
Conditions
Social Acceptance
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Tristen Inagaki
Other
Eligibility
18 Years to 35 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 26, 2026, 2:46 AM EDT
Recruiting Not applicable Interventional

Empowering Caregivers to Promote Child Independence

NCT07059364
View directory record Official record
Conditions
Profound Autism
Interventions
CAST Treatment
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
10 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 26, 2026, 2:46 AM EDT